http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-102670520-B
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_fd7c916555e5b01cd17634c7296d39b6 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-34 |
| filingDate | 2011-08-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2014-02-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_28742968a081986c272a56fb941a62a4 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6e02420d8d8404831fbfb45382f045c8 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bf41bbbabc1e4d7463d93fd28b93b8c8 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4741d4c78cef62ca13449949df2b02f4 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_17e4cc7c3e8d524449f554c4df7f5890 |
| publicationDate | 2014-02-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-102670520-B |
| titleOfInvention | Chemotherapy drug pulse sustained-release implant agent and preparation method thereof |
| abstract | The invention provides a chemotherapy drug pulse sustained-release implant agent and a preparation method thereof. The sustained-release implant agent comprises a chemotherapy drug active component such as any one of gemcitabine, gemcitabine hydrochloride, doxorubicin, 5-fluorouracil, cisplatin, carboplatin and paclitaxel, and an excipient such as a polylactic-glycolic acid copolymer. The preparation method provided by the invention comprises the following steps of: evenly mixing the chemotherapy drug active component with the excipient in a solvent, and then drying the mixture of the chemotherapy drug active component and the excipient in a vacuum after removing the solvent; and then sequentially crushing, sieving, melting and blending the mixture to obtain the sustained-release implant agent. The sustained-release implant agent provided by the invention has the advantages that a second drug release is carried out after tumor growth is controlled by a first drug release for a certain period, and the local effective concentration of a drug is effectively increased, so that the effect of administering once and releasing twice is achieved, and the side injury caused by secondary drug implanting is avoided. |
| priorityDate | 2011-03-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 45.